Innovative ETFs Content Hub Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
ETF Building Blocks Content Hub How Increased FDA Activity Can Benefit ETFs in Your Portfolio By Tom LydonNovember 19, 2020
ETF Building Blocks Content Hub A Healthcare ETF Review: Biotech Beckons under Biden By Tom LydonNovember 9, 2020
ETF Building Blocks Content Hub More than Just COVID: Hot ETFs for Medical Breakthroughs By Tom LydonNovember 5, 2020
ETF Building Blocks Content Hub For 2021 Upside, Bet on the SBIO Biotech ETF By Tom LydonOctober 29, 2020
ETF Building Blocks Content Hub Post-Election Considerations for a Nifty Biotech ETF By Tom LydonOctober 7, 2020
ETF Building Blocks Content Hub Election Impact Could Be Muted, Biotech Still Appealing By Todd ShriberSeptember 29, 2020
ETF Building Blocks Content Hub Acquisitions & Postive Drug Data Boost SBIO ETF Again By Special To VettaFiAugust 25, 2020
ETF Building Blocks Content Hub When Innovation and Being Nimble Matters, Turn to this Biotech ETF By Tom LydonAugust 3, 2020
ETF Building Blocks Content Hub Betting on Biotech With Utility Beyond Covid-19 By Tom LydonJuly 31, 2020
ETF Building Blocks Content Hub Fabulous Fundamentals Brighten Outlook for Healthcare, With This Biotech ETF By Tom LydonJuly 7, 2020
ETF Building Blocks Content Hub Another Round of Coronavirus Cases Puts This Biotech ETF in Focus By Tom LydonJune 29, 2020
ETF Building Blocks Content Hub A Healthcare ETF Could Benefit From Index Reshuffling By Tom LydonJune 23, 2020
ETF Building Blocks Content Hub Biotech ETFs in the Spotlight, Why They’ll Remain There By Tom LydonJune 18, 2020
ETF Building Blocks Content Hub Biotech ETF Doesn’t Need Coronavirus Vaccines to Soar By Tom LydonJune 2, 2020
